Industry

Financing round led by Jeito Capital and co-led by Forbion Growth, with participation from Seroba, Pictet Group and other existing investors Proceeds to fund two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses as well as expanding the Azafaros pipeline to other indications Nizubaglustat has been … [Read more…]

TOKYO & WALTHAM, Mass.–(BUSINESS WIRE)–Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases utilizing its proprietary CRISPR-GNDM® epigenome editing technology, announced its recognition as a top eight finalist in the prestigious XPRIZE Healthspan competition’s FSHD Bonus Prize and award of $250,000 for demonstrating a … [Read more…]

Announced capsid license agreement with Lilly to deliver genomic medicines for up to five central nervous system (CNS) disease targets. Received $18 million upfront license fee for first target and eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments, plus tiered royalties on potential net sales. Announced derisking milestones … [Read more…]

RICHMOND, Calif.–(BUSINESS WIRE)–Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. Eastern on Monday, May 12 will be postponed to 6:30p.m. Eastern on Monday, May 12, 2025. The registration and access link previously provided remains the same. Participants should register for, and access, … [Read more…]

Chief Legal and Policy Officer, Steven Newmark, Joins Policy Briefing with Assemblymember Amanda Septimo and the Community Liver Alliance UPPER NYACK, N.Y.–(BUSINESS WIRE)–Steven Newmark, Chief Legal and Policy Officer of the Global Healthy Living Foundation (GHLF), takes the organization’s national 340B reform message to a policy briefing in Albany, NY, on May 13, addressing the … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Pharmaceutical Regulatory Affairs in China Training Course (ONLINE EVENT: June 25-26, 2025)” has been added to ResearchAndMarkets.com’s offering. Explore the comprehensive landscape of pharmaceutical marketing authorization in China, including Hong Kong, Macau, and Taiwan, through this specialized two-day seminar. This seminar will provide an invaluable overview of how to gain and maintain a … [Read more…]

For the three months ended March 31, 2025—marking the first quarter with a permanent J-code that streamlined billing and reimbursement for prescribing providers—ImmunityBio achieved net product revenue of approximately $16.5 million, representing a 129% increase over $7.2 million in Q4 2024. ANKTIVA® unit sales volume in Q1 2025 grew 150% over Q4 2024, with monthly … [Read more…]

Creates ~$1.5 billion revenue company in fast-growing collagen-based health, nutrition and food sectors 85% owned and consolidated by Darling Ingredients Non-cash transaction, combining assets, capabilities Strengthens foundation around serving food and pharma customers Provides a platform for accelerated product development and growth Creates an opportunity to unlock significant shareholder value IRVING, Texas–(BUSINESS WIRE)–$DAR—Darling Ingredients Inc. … [Read more…]

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that its B-cell lymphoma-2 (BCL2) inhibitor, Mesutoclax (ICP-248), has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment … [Read more…]

SINGAPORE & WILMINGTON, Del.–(BUSINESS WIRE)–Nanyang Biologics (NYB) and Precisya Global Inc (PGI) announce a strategic collaboration to leverage our technologies in validating potential therapeutic benefits of natural compounds against genetically identified risk factors and predispositions for chronic diseases. The partnership combines PGI’s genomic big data analytics with NYB’s natural compound libraries and AI capabilities. The … [Read more…]